Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from a phase 3 trial of gefurulimab, a once-weekly self-administered treatment ...

The pharmaceutical giant sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it currently sells for  myasthenia gravis.

(Alliance News) - AstraZeneca PLC on Thursday said its investigational complement C5 inhibitor gefurulimab showed statistically significant results in treating adults with a form of generalised ...

UK pharma major AstraZeneca is preparing to advance gefurulimab as a potential new treatment for generalized myasthenia ...

The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...

AstraZeneca announced on Thursday that its investigational treatment ‘gefurulimab’ achieved statistically significant and ...

The global Enzyme Replacement Therapy (ERT) market is poised for significant expansion, projected to reach USD 21.62 billion ...

Ascendis’ likely approval of TransCon CNP for achondroplasia poses a major threat to BioMarin’s best-selling drug. Read why I ...

The announcement by AstroZeneca follows a growing trend of companies pledging to invest in pharmaceutical manufacturing on American soil in pursuit of appeasing President Donald Trump as he threatens ...

Real Chemistry’s latest acquisition adds up to Greater Than One. | Greater Than One will retain its name and New York City headquarters as it moves under the Real Chemistry umbrella, and its employees ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

The time variable is fundamental in medicine. Also and above all if it is a question of reaching a diagnosis of a rare disease by definition more difficult to discover. But to improve the situation ...